• The laboratory of physiopathology of bone resorption was created in 1999 by Dominique HEYMANN (researcher) and François GOUIN (surgeon). The objective was to study the molecular and cellular mechanisms that regulate the development of bone pathologies of tumor origin through approaches that involve basic research, preclinical studies and clinical trials.
  • This theme, unique in Europe, allowed us to develop our field with the arrival of several researchers and to obtain in 2009 an INSERM label (UMR957) renewed in 2012. The research project evolved to focus not only on bone sarcomas, but also on vascular calcifications, arthritis and unconsolidated fractures.
  • 2017 begins with the creation of the UMR1238 unit, a new head manager (Françoise REDINI) and 3 research teams with complementary objectives in bone diseases.

More Data

1999: Creation of the laboratory of pathophysiology of bone resorption by Dominique HEYMANN and François GOUIN.     
2004: The label "team d'accueil" of the University and the label "team region INSERM" are obtained - 11 persons work in the laboratory.        

2009: The laboratory obtains the label unit INSERM-University of Nantes and allows the recruitment of researchers and technicians. The UMR 957 is a monothematic unit.        

2012: The INSERM - University label is renewed. The name of the laboratory evolves towards: Laboratory of physiopathology of bone resorption and therapy of primary bone tumors. In the same year the laboratory obtained a label "team Ligue contre le Cancer" for 5 years. 50 persons work in the laboratory.        

2017: The direction and name of the laboratory change. Françoise REDINI manages the new Unit UMR1238, bone sarcomas and remodeling of calcified tissue with 3 research teams.

Our achievements

At scientist level

  • Therapeutic targeting of bone cells in the tumor microenvironment:  publications in Cancer Res (2010), J Bone Min Res (2011), Bone (2014), BMC Cancer (2015) and Lancet Oncol (2016)
  • Epigenetics: JQ1 is an inhibitor of BET bromodomain proteins capable of interfering with the development of osteosarcomas: publication in Nature Comm (2014), Bone (2016) and Oncotarget (2016)
  • Characterization of the Effect of IL 34 on Bone Physiopathology: publications in J Pathol (2010), Annals Rheum Dis (2012), Int J Cancer (2015), Am J Pathol (2017)
  • Bone regeneration and 3D culture. Publications dans Biomaterials (2014), Acta Biomaterialia (2014), Biomed Mater (2016) and a patent filed in 2014
  • Inflammatory cytokines of the family IL6 and IL1 involved in the development of primary bone tumors, in bone regeneration and arthritis. Publications in Stem Cells (2012), Am J Pathol (2015), Clin Exp Immunol (2016)
  • Identification of cytokines of the TGFb family in the metastatic potential of bone tumors. Publications in Clin Cancer Res (2014), Oncotarget (2015) and J Clin Med (2016)
  • TNF family cytokines involved in the development of bone tumors and associated osteolysis. Publications in Clin Cancer Res (2010), Mol Cancer Res (2012) and Int J Cancer (2016)
  • Characterization of the tumor bone niche and impact of mesenchymal stem cells. Publications in Plos One (2010) Plastic Reconstructive Surgery (2015), J Bone Oncol (2015) and Stem Cells (2017)

Congress Organizations

  • For national congress :
    • Journées Françaises de Biologie des Tissus Minéralisés (05/2013),
    • Journée BIOSARC (09/2013),
    • GSF- GETO (06/2014),
    • Workshop du Cancéropôle Grand Ouest (10/2014),
    • Séminaire CIMATH : "Molecular targeting and therapeutic applications" (09/2014)
    • Colloque « Niches et Cancer » du Cancéropôle Grand Ouest (09/2015)
  • for international congress :
    • European Research Orthopaedic Society (07/2014)
    • Workshop of Cancéropôle Grand-Ouest (10/2015)
    • EMSOS (05/2016)
    • Hypoxia (10/2016)

At economic and cultural level

  •   Close partnership with patient associations and foundations
  • Animations towards general public